Molecular imaging of gliomas with PET: Opportunities and limitations

Neuro-Oncology

Volumn 13, Issue 8, 2011, Pages 806-819

  La Fougère, Christian ^a   Suchorska, Bogdana ^a   Bartenstein, Peter ^a   Kreth, Friedrich Wilhelm ^a   Tonn, Jörg Christian ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Glioma; Molecular imaging; PET

Indexed keywords

6 FLUORODOPA F 18; CARBON 11; FLUORINE 18; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; GLUCOSE TRANSPORTER; METHIONINE C 11; NITROGEN 13; OXYGEN 15; TRACER;

AMINO ACID TRANSPORT; BIOSYNTHESIS; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; GLIOMA; GLUCOSE METABOLISM; HUMAN; MOLECULAR IMAGING; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN SYNTHESIS; REVIEW;

ANIMALS; BRAIN NEOPLASMS; DIAGNOSTIC IMAGING; GLIOMA; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 80052714649     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor054     Document Type: Review

References (119)

1. Waldman AD, Jackson A, Price SJ, et al. Quantitative imaging biomarkers in neuro-oncology. Nat Rev Clin Oncol. 2009;6: 445-454.
2. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2:683-693. (Pubitemid 37328919)
3. Alavi A, Dann R, Chawluk J, Alavi J, Kushner M, Reivich M. Positron emission tomography imaging of regional cerebral glucose metabolism. Semin Nucl Med. 1986;16:2-34.
4. Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol. 1987;22:360-371. (Pubitemid 17074568)
5. Di Chiro G, DeLaPaz RL, Brooks RA, et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology. 1982;32:1323-1329. (Pubitemid 13218489)
6. Alavi JB, Alavi A, Chawluk J, et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer. 1988;62:1074-1078.
7. Nagamatsu S, Sawa H,Wakizaka A, Hoshino T. Expression of facilitative glucose transporter isoforms in human brain tumors. J Neurochem. 1993;61:2048-2053. (Pubitemid 23354060)
8. Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR Am J Neuroradiol. 1998;19:407-413. (Pubitemid 30422740)
9. Weber W, Bartenstein P, Gross MW, et al. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. J Nucl Med. 1997;38:802-808.
10. Schifter T, Hoffman JM, Hanson MW, et al. Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. J Comput Assist Tomogr. 1993;17:509-561.
11. Hubner KF, Purvis JT, Mahaley SM, Jr, et al. Brain tumor imaging by positron emission computed tomography using 11C-labeled amino acids. J Comput Assist Tomogr. 1982;6:544-550. (Pubitemid 12123043)
12. Isselbacher KJ. Sugar and amino acid transport by cells in culture-differences between normal and malignant cells. N Engl J Med. 1972;286:929-933.
13. Ishiwata K, Kubota K, Murakami M, et al. Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med. 1993;34:1936-1943. (Pubitemid 23331262)
14. Derlon JM, Bourdet C, Bustany P, et al. [11C]L-methionine uptake in gliomas. Neurosurgery. 1989;25:720-728.
15. Wienhard K, Herholz K, Coenen HH, et al. Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine. J Nucl Med. 1991;32:1338-1346.
16. Heiss P, Mayer S, Herz M, et al. Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med. 1999;40:1367-1373. (Pubitemid 29385647)
17. Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40:205-212. (Pubitemid 29044193)
18. Chen W, Silverman DH, Delaloye S, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006;47:904-911. (Pubitemid 46939941)
19. Langen KJ, Ziemons K, Kiwit JC, et al. 3-[123I]iodo-alphamethyltyrosine and [methyl-11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. J Nucl Med. 1997;38:517-522.
20. Weber WA, Wester HJ, Grosu AL, et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumors: initial results of a comparative study. Eur J Nucl Med. 2000;27:542-549. (Pubitemid 30262620)
21. Ishiwata K, Vaalburg W, Elsinga PH, Paans AM, Woldring MG. Comparison of L-[1-11C]methionine and L-methyl-[11C]methionine for measuring in vivo protein synthesis rates with PET. J Nucl Med. 1988;29:1419-1427.
22. Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007;48:1468-1481. (Pubitemid 47397397)
23. Sasajima T, Miyagawa T, Oku T, Gelovani JG, Finn R, Blasberg R. Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines. Eur J Nucl Med Mol Imaging. 2004;31:1244-1256. (Pubitemid 39222488)
24. Roelcke U, Radu EW, von Ammon K, Hausmann O, Maguire RP, Leenders KL. Alteration of blood-brain barrier in human brain tumors: comparison of [18F]fluorodeoxyglucose, [11C]methionine and rubidium-82 using PET. J Neurol Sci. 1995;132:20-27.
25. Torii K, Tsuyuguchi N, Kawabe J, Sunada I, Hara M, Shiomi S.Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas. Ann Nucl Med. 2005;19:677-683. (Pubitemid 43175528)
26. Popperl G, Kreth FW, Mehrkens JH, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumor grading. Eur J Nucl Med Mol Imaging. 2007;34:1933-1942. (Pubitemid 350212135)
27. Krohn KA, Mankoff DA, Eary JF. Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol. 2001;(Suppl. 41):96S-103S. (Pubitemid 32612429)
28. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336. (Pubitemid 28512118)
29. Kong XB, Zhu QY, Vidal PM, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother. 1992;36:808-818.
30. Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005;46:945-952. (Pubitemid 43733508)
31. Jacobs AH, Thomas A, Kracht LW, et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46:1948-1958. (Pubitemid 46657440)
32. Zeisel SH. Dietary choline: biochemistry, physiology, and pharmacology. Annu Rev Nutr. 1981;1:95-121.
33. Podo F. Tumor phospholipid metabolism. NMR Biomed. 1999;12:413-439.
34. Kwee SA, Ko JP, Jiang CS, Watters MR, Coel MN. Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET. Radiology. 2007;244:557-565. (Pubitemid 47080889)
35. Kato T, Shinoda J, Nakayama N, et al. Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol. 2008;29:1176-1182. (Pubitemid 351954890)
36. Denny WA. Prodrug strategies in cancer therapy. Eur J Med Chem. 2001;36:577-595. (Pubitemid 32964730)
37. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med. 1992;33:2133-2137.
38. Reischl G, Ehrlichmann W, Bieg C, et al. Preparation of the hypoxia imaging PET tracer [18F]FAZA: reaction parameters and automation. Appl Radiat Isot. 2005;62:897-901. (Pubitemid 40432058)
39. Whitmore GF, Varghese AJ. The biological properties of reduced nitroheterocyclics and possible underlying biochemical mechanisms. Biochem Pharmacol. 1986;35:97-103. (Pubitemid 16161371)
40. Cher LM, Murone C, Lawrentschuk N, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med. 2006;47:410-418. (Pubitemid 46768482)
41. Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F- fluoromisonidazole and 15O-H2O. J Nucl Med. 2004;45: 1851-1859. (Pubitemid 47618442)
42. Swanson KR, Chakraborty G, Wang CH, et al. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med. 2009;50:36-44.
43. Hustinx R, Eck SL, Alavi A. Potential applications of PET imaging in developing novel cancer therapies. J Nucl Med. 1999;40:995-1002. (Pubitemid 29269221)
44. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
45. Bacharach SL, Libutti SK, Carrasquillo JA. Measuring tumor blood flow with H(2)(15)O: practical considerations. Nucl Med Biol. 2000;27:671-676.
46. Herholz K, Pietrzyk U, Voges J, et al. Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg. 1993;79:853-858. (Pubitemid 23342449)
47. Goldman S, Levivier M, Pirotte B, et al. Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. Cancer. 1996;78:1098-1106. (Pubitemid 26284876)
48. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med. 1998;39:778-785. (Pubitemid 28216722)
49. De Witte O, Levivier M, Violon P, et al. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery. 1996;39:470-476; discussion 476-477.
50. Patronas NJ, Di Chiro G, Kufta C, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg. 1985;62:816-822. (Pubitemid 15009404)
51. Pauleit D, Stoffels G, Bachofner A, et al. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol. 2009;36:779-787.
52. Spence AM, Muzi M, Mankoff DA, et al. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med. 2004;45:1653-1659. (Pubitemid 47618471)
53. Herholz K, Holzer T, Bauer B, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316-1322. (Pubitemid 28240345)
54. Fueger BJ, Czernin J, Cloughesy T, et al. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med. 2010;51: 1532-1538.
55. Kunz M, Thon N, Eigenbrod S, et al. Hot spots in 18FET-PET delineate malignant tumor parts within suspected WHO grade II glioma. Neuro Oncol. 2011;13:307-316.
56. Moulin-Romsee G, D'Hondt E, de Groot T, et al. Non-invasive grading of brain tumors using dynamic amino acid PET imaging: does it work for 11C-methionine? Eur J Nucl Med Mol Imaging. 2007;34:2082-2087. (Pubitemid 350212139)
57. Floeth FW, Pauleit D, Sabel M, et al. 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med. 2006;47:776-782. (Pubitemid 46768440)
58. Mineura K, Sasajima T, Kowada M, Ogawa T, Hatazawa J, Uemura K. Indications for differential diagnosis of nontumor central nervous system diseases from tumors. A positron emission tomography study. J Neuroimaging. 1997;7:8-15. (Pubitemid 27069294)
59. Sasaki M, Ichiya Y, Kuwabara Y, et al. Ringlike uptake of [18F]FDG in brain abscess: a PET study. J Comput Assist Tomogr. 1990;14:486-487. (Pubitemid 20162584)
60. Tsuyuguchi N, Sunada I, Ohata K, et al. Evaluation of treatment effects in brain abscess with positron emission tomography: comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine. Ann Nucl Med. 2003;17:47-51. (Pubitemid 36417573)
61. Jacobs AH, Kracht LW, Gossmann A, et al. Imaging in neurooncology. NeuroRx. 2005;2:333-347. (Pubitemid 40471440)
62. Huang Z, Zuo C, Guan Y, et al. Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumors. Nucl Med Commun. 2008;29:354-358. (Pubitemid 351644384)
63. Ishii K, Ogawa T, Hatazawa J, et al. High L-methyl-[11C]methionine uptake in brain abscess: a PET study. J Comput Assist Tomogr. 1993;17:660-661. (Pubitemid 23206756)
64. Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology. 2002;59:947-949.
65. Barker FG, 2nd, Chang SM, Huhn SL, et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer. 1997;80:936-941. (Pubitemid 27360923)
66. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003;24:1989-1998. (Pubitemid 37444849)
67. Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol. 2001;3:193-200. (Pubitemid 33674111)
68. Pirotte BJ, Lubansu A, Massager N, Wikler D, Goldman S, Levivier M. Results of positron emission tomography guidance and reassessment of the utility of and indications for stereotactic biopsy in children with infiltrative brainstem tumors. J Neurosurg. 2007;107:392-399.
69. Levivier M, Goldman S, Pirotte B, et al. Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F] fluorodeoxyglucose. J Neurosurg. 1995;82:445-452.
70. Pauleit D, Floeth F, Hamacher K, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128: 678-687. (Pubitemid 40380202)
71. Pirotte B, Goldman S, Massager N, et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med. 2004;45:1293-1298. (Pubitemid 47618525)
72. Price SJ, Fryer TD, Cleij MC, et al. Imaging regional variation of cellular proliferation in gliomas using 3?-deoxy-3?-[18F]fluorothymidine positron-emission tomography: an image-guided biopsy study. Clin Radiol. 2009;64:52-63.
73. Tanaka Y, Nariai T, Momose T, et al. Glioma surgery using a multimodal bnavigation system with integrated metabolic images. J Neurosurg. 2009;110:163-172.
74. Pirotte BJ, Levivier M, Goldman S, et al. Positron emission tomographyguided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery. 2009;64:471-481; discussion 481.
75. Stockhammer F, Misch M, Horn P, Koch A, Fonyuy N, Plotkin M. Association of F18-fluoro-ethyl-tyrosin uptake and 5-aminolevulinic acid-induced fluorescence in gliomas. Acta Neurochir (Wien). 2009;151:1377-1383.
76. Grosu AL, Piert M, Weber WA, et al. Positron emission tomography for radiation treatment planning. Strahlenther Onkol. 2005;181: 483-499. (Pubitemid 41059518)
77. Ling CC, Humm J, Larson S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47:551-560. (Pubitemid 30317470)
78. Grosu AL, Weber WA, Franz M, et al. Reirradiation of recurrent highgrade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:511-519. (Pubitemid 41317169)
79. Grosu AL, Weber WA, Riedel E, et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:64-74. (Pubitemid 41583543)
80. Weber DC, Zilli T, Buchegger F, et al. [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma. Radiat Oncol. 2008;3:44.
81. Lee IH, Piert M, Gomez-Hassan D, et al. Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009;73:479-485.
82. Gross MW, Weber WA, Feldmann HJ, Bartenstein P, Schwaiger M, Molls M. The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys. 1998;41:989-995. (Pubitemid 28377478)
83. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
84. de Wit MC, de Bruin HG, EijkenboomW, Sillevis Smitt PA, van den Bent MJ. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology. 2004;63:535-537. (Pubitemid 39031388)
85. Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology. 2000;217:377-384.
86. Yang I, Aghi MK. New advances that enable identification of glioblastoma recurrence. Nat Rev Clin Oncol. 2009;6:648-657.
87. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9:453-461. (Pubitemid 351597795)
88. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963-1972.
89. Charnley N, West CM, Barnett CM, et al. Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:331-338. (Pubitemid 44332726)
90. Marriott CJ, Thorstad W, Akabani G, et al. Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors. J Nucl Med. 1998;39:1376-1380.
91. Cao Y, Tsien CI, Shen Z, et al. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol. 2005;23:4127-4136. (Pubitemid 46211318)
92. Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med. 2000;41:1861-1867.
93. Chao ST, Suh JH, Raja S, Lee SY, Barnett G. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer. 2001;96:191-197. (Pubitemid 32520674)
94. Barker FG, 2nd, Chang SM, Valk PE, Pounds TR, Prados MD. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer. 1997;79:115-126. (Pubitemid 26425516)
95. Wurker M, Herholz K, Voges J, et al. Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy. Eur J Nucl Med. 1996;23:583-586. (Pubitemid 26140591)
96. Ullrich RT, Kracht L, Brunn A, et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med. 2009;50:1962-1968.
97. Terakawa Y, Tsuyuguchi N, Iwai Y, et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med. 2008;49:694-699. (Pubitemid 351717532)
98. Van Laere K, Ceyssens S, Van Calenbergh F, et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging. 2005;32:39-51. (Pubitemid 40142777)
99. Mehrkens JH, Popperl G, Rachinger W, et al. The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol. 2008;88:27-35.
100. Popperl G, Gotz C, Rachinger W, et al. Serial O-(2-[(18)F]fluoroethyl)-L: -tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging. 2006;33:792-800. (Pubitemid 43979687)
101. Zeng QS, Li CF, Zhang K, Liu H, Kang XS, Zhen JH. Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury. J Neurooncol. 2007;84:63-69. (Pubitemid 47103445)
102. Rachinger W, Goetz C, Popperl G, et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery. 2005;57:505-511; discussion 505-511. (Pubitemid 41254459)
103. Popperl G, Goldbrunner R, Gildehaus FJ, et al. O-(2-[18F]fluoroethyl)-L- tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2005;32:1018-1025. (Pubitemid 41339276)
104. Nariai T, Tanaka Y, Wakimoto H, et al. Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg. 2005;103:498-507. (Pubitemid 43186642)
105. Rueger MA, Ameli M, Li H, et al. [(18)F]FLT PET for non-invasive monitoring of early response to gene therapy in experimental gliomas. Mol Imaging Biol. 2011;13:547-557.
106. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006;66:1258-1260. (Pubitemid 43739717)
107. Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714-4721. (Pubitemid 350086472)
108. Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol. 2008;26:271-278.
109. Claus EB, Black PM. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001. Cancer. 2006;106:1358-1363. (Pubitemid 43363915)
110. Floeth FW, Pauleit D, Sabel M, et al. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med. 2007;48:519-527. (Pubitemid 47571405)
111. Padma MV, Said S, Jacobs M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol. 2003;64:227-237. (Pubitemid 37203463)
112. Tabatabai G, Stupp R, van den Bent MJ, et al. Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol. 2010;120:585-592.
113. Haubner R, Kuhnast B, Mang C, et al. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem. 2004;15:61-69. (Pubitemid 38165981)
114. Schnell O, Krebs B, Carlsen J, et al. Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol. 2009;11:861-870.
115. Gladson CL. Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J Neuropathol Exp Neurol. 1996;55: 1143-1149. (Pubitemid 26372791)
116. Schnell O, Krebs B, Wagner E, et al. Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol. 2008;18:378-386. (Pubitemid 351782847)
117. Tavitian B. In vivo antisense imaging. Q J Nucl Med. 2000;44:236-255.
118. Tavitian B, Terrazzino S, Kuhnast B, et al. In vivo imaging of oligonucleotides with positron emission tomography. Nat Med. 1998;4:467-471.
119. Lendvai G, Estrada S, Bergstrom M. Radiolabelled oligonucleotides for imaging of gene expression with PET. Curr Med Chem. 2009;16:4445-4461.